Glaukos Corp
$ 124.79
2.61%
17 Apr - close price
- Market Cap 7,118,081,000 USD
- Current Price $ 124.79
- High / Low $ 127.00 / 123.41
- Stock P/E N/A
- Book Value 11.41
- EPS -3.28
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.26 %
- 52 Week High 130.23
- 52 Week Low 73.16
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Analyst Target Price
$138.92
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-10-29 | 2025-07-30 | 2025-04-29 | 2025-02-19 | 2024-11-04 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.9 | -0.16 | -0.24 | -0.22 | -0.4 | -0.28 | -0.52 | -0.7 | -0.63 | -0.5 | -0.55 | -0.59 |
| Estimated EPS | -0.21 | -0.26 | -0.26 | -0.3556 | -0.3885 | -0.48 | -0.51 | -0.57 | -0.55 | -0.55 | -0.55 | -0.58 |
| Surprise | -0.69 | 0.1 | 0.02 | 0.1356 | -0.0115 | 0.2 | -0.01 | -0.13 | -0.08 | 0.05 | 0 | -0.01 |
| Surprise Percentage | -328.5714% | 38.4615% | 7.6923% | 38.1327% | -2.9601% | 41.6667% | -1.9608% | -22.807% | -14.5455% | 9.0909% | 0% | -1.7241% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GKOS
2026-04-17 05:09:26
Glaukos Corporation has released its 2025 Sustainability Report, outlining significant progress in corporate sustainability initiatives. The report highlights achievements such as over $22 million in product donations, 870 employee volunteer hours, and FDA approval for Epioxa™, underscoring the company's commitment to innovation, ethics, and community support. The initiatives are overseen by the company's board of directors and aligned with Glaukos' mission as a global healthcare leader.
2026-04-16 14:39:09
Glaukos announced that its Epioxa (Epioxa HD / Epioxa) keratoconus treatment has been assigned a permanent HCPCS J-code (J2789) by the U.S. Centers for Medicare and Medicaid Services, effective July 1, 2026. This J-code is expected to simplify reimbursement and improve market access for patients. The company's shares gained 0.4% following the news, and the assignment positions Glaukos for continued growth in the corneal therapies market, which is projected to reach $584.6 million in 2026.
2026-04-16 09:39:09
This article announces an ARS SEC filing by GLAUKOS Corp (GKOS) on April 16, 2026, at 06:05 AM. The filing is categorized with a low impact and neutral sentiment. The article also provides a brief overview of Glaukos Corp's stock performance, company details, and recent news and SEC filings.
2026-04-16 07:39:09
Glaukos Corporation has announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J2789) for Epioxa™ HD / Epioxa™. This J-code will become effective on July 1, 2026, and is expected to streamline the reporting and payment of Epioxa by U.S. payers for the treatment of keratoconus. Epioxa offers an incision-free alternative to traditional corneal cross-linking procedures, aiming to reduce pain and recovery time for patients.
2026-04-16 04:10:37
Glaukos Corporation has announced that the U.S. Centers for Medicare and Medicaid Services (CMS) assigned a permanent J-code (J2789) for its Epioxa HD and Epioxa treatments for keratoconus, effective July 1, 2026. This new J-code is expected to streamline reporting and payment, improving patient access and coverage for this innovative, incision-free therapy. The development is a significant milestone for Glaukos in expanding market access for keratoconus patients.
2026-04-16 04:04:37
Glaukos Corporation announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (J-code) for its product Epioxa HD / Epioxa. This new J-code, J2789, will become effective on July 1, 2026, and is expected to streamline reporting and payment for Epioxa, which is used to treat keratoconus. Glaukos's CEO, Thomas Burns, stated that this is an important milestone for market access, aiming to increase coverage and access for patients with the sight-threatening disease.
